The Medical Letter on Drugs and Therapeutics
Seasonal Trivalent Influenza Vaccine for 2009-2010
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing pandemic infection.1 The next issue of the Medical Letter will review the pandemic H1N1 vaccine.

SEASONAL VACCINE FOR 2009-2010 — The usual seasonal influenza vaccine is available in inactivated and live attenuated formulations. Both include the same influenza A antigens as 2008-2009, A/Brisbane/59/2007 (H1N1)-like and A/Brisbane/10/2007 H3N2-like, and a new influenza B antigen, B/Brisbane/60/2008. This vaccine is not expected to offer any protection against the pandemic strain.2

WHO SHOULD BE VACCINATED — Vaccination against seasonal influenza is most important for persons at high risk of influenza complications, including children ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Seasonal Trivalent Influenza Vaccine for 2009-2010
Article code: 1321a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian